AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32654663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 26
Study 32654663 — intervention group
Group type: COMPARATOR
Intervention: Ferric derisomaltose (FDI)
Number of subjects: 26
Study 36775528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training 3 times a week for 8 weeks
Number of subjects: 42
Study 36775528 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program for 8 weeks (Control Group)
Number of subjects: 42
Study 34477139 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 168
Study 34477139 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection and splint treatment
Number of subjects: 168
Study 34750225 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (dAMPH)
Number of subjects: 17
Study 34750225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 33885235 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg astaxanthin orally daily
Number of subjects: 80
Study 33885235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35434911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle-related risk factor modification intervention
Number of subjects: 224
Study 35434911 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 224
Study 33758940 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable Intervention (VI) - daily provision of vegetables in amounts and types recommended by the DGA (∼270 g/day) for 8 weeks
Number of subjects: 110
Study 33758940 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 110
Study 32854965 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Acute and Post‐acute Fall Prevention intervention
Number of subjects: 110
Study 32854965 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 36463266 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive memory training
Number of subjects: 96
Study 36463266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham intervention
Number of subjects: 96
Study 36463266 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 96
Study 36463266 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive memory training and Sham intervention
Number of subjects: 96
Study 33840085 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40
Study 33840085 — intervention group
Group type: COMPARATOR
Intervention: Terazosin plus Enalapril
Number of subjects: 40
Study 35241176 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional standing frame programme (30 min. standing plus sit‐to‐stand repetitions) plus 15 min of usual physiotherapy daily
Number of subjects: 45
Study 35241176 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy (45 min) daily
Number of subjects: 45
Study 35768113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 8 weeks preoperatively
Number of subjects: 500
Study 35768113 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules daily for 8 weeks preoperatively
Number of subjects: 500
Study 34418380 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced postoperative surveillance interventions (admitting to higher care ward, increasing nursing observations, assigning bed in view of nursing station, allowing family members to stay, placing surveillance guide at bedside)
Number of subjects: 28892
Study 34418380 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (control group)
Number of subjects: 28892
Study 34418380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (intervention group)
Number of subjects: 28892
Study 34418380 — intervention group
Group type: COMPARATOR
Intervention: Low-risk patients (control group)
Number of subjects: 28892
Study 32623402 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium breve A1 (2×10^10 CFU)
Number of subjects: 80
Study 32623402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34282985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with alteplase
Number of subjects: 113
Study 34282985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with alteplase (baseline ≥5 cerebral microbleeds)
Number of subjects: 113
Study 34142636 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance Behavior (AB)
Number of subjects: 428
Study 34142636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitions (COG)
Number of subjects: 428
Study 34343140 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative therapies such as exercise, respiratory muscle training, assistive devices, and manual therapy and stretching
Number of subjects: 0
Study 34343140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trials
Number of subjects: 0
Study 34343140 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative exercise programs
Number of subjects: 0
Study 34343140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehab
Number of subjects: 0
Study 32599148 — intervention group
Group type: EXPERIMENTAL
Intervention: System-level intervention to improve serious illness communication
Number of subjects: 0
Study 32599148 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Priorities Scale (nonvalidated survey)
Number of subjects: 0
Study 36070584 — intervention group
Group type: EXPERIMENTAL
Intervention: MWF + activeDL
Number of subjects: 18
Study 36070584 — intervention group
Group type: COMPARATOR
Intervention: MWF alone
Number of subjects: 18
Study 35665947 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days amoxicillin 1 g + clarithromycin 500 mg + vonoprazan 20 mg twice per day
Number of subjects: 244
Study 35665947 — intervention group
Group type: COMPARATOR
Intervention: 14 days amoxicillin 1 g + clarithromycin 500 mg + PPI (omeprazole or esomeprazole or rabeprazole) 20 mg twice/day
Number of subjects: 244
Study 33676366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) intake
Number of subjects: 32
Study 33676366 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat intake
Number of subjects: 32
Study 33676366 — intervention group
Group type: COMPARATOR
Intervention: Control (no SSB or meat intake)
Number of subjects: 32
Study 32871029 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-DXM plus rhTPO
Number of subjects: 196
Study 32871029 — intervention group
Group type: COMPARATOR
Intervention: HD-DXM monotherapy
Number of subjects: 196
Study 35222267 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy with saline irrigation during the early mid‐follicular phase (day 5‐7) of a stimulation cycle.
Number of subjects: 228
Study 35222267 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (control group).
Number of subjects: 228
Study 33207997 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxoplasma-seropositive mothers (case group)
Number of subjects: 137
Study 33207997 — intervention group
Group type: COMPARATOR
Intervention: Toxoplasma-seronegative mothers (control group)
Number of subjects: 137
Study 32233570 — intervention group
Group type: EXPERIMENTAL
Intervention: Invariant probability measure $
u_{	ext{λ}}^*$
Number of subjects: 0
Study 35322134 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke evacuation system (SES)
Number of subjects: 122
Study 35322134 — intervention group
Group type: COMPARATOR
Intervention: No smoke evacuation system (no SES)
Number of subjects: 122
Study 32008730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone 400 mg twice daily
Number of subjects: 4153
Study 32008730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4153
Study 36348211 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-app intervention for 6 months based on the Behaviour Change Wheel Model
Number of subjects: 224
Study 36348211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no web-app intervention)
Number of subjects: 224
Study 34391272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational movement exercises (16 training sessions over 4 weeks)
Number of subjects: 73
Study 34391272 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no training applied
Number of subjects: 73
Study 32471476 — intervention group
Group type: EXPERIMENTAL
Intervention: NUCOD program delivered through trained diabetes nurses
Number of subjects: 1236
Study 32471476 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment group
Number of subjects: 1236
Study 32471476 — intervention group
Group type: EXPERIMENTAL
Intervention: NUCOD program
Number of subjects: 1236
Study 36397237 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive return to work intervention including educational material, face-to-face educational session, and individualized telephone counseling sessions.
Number of subjects: 0
Study 36397237 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive return to work intervention
Number of subjects: 0
Study 34235780 — intervention group
Group type: EXPERIMENTAL
Intervention: Air mixed with emissions from cooking (PM2.5: 96.1 μg/m3)
Number of subjects: 36
Study 34235780 — intervention group
Group type: EXPERIMENTAL
Intervention: Air mixed with emissions from candles (PM2.5: 89.8 μg/m3)
Number of subjects: 36
Study 34235780 — intervention group
Group type: COMPARATOR
Intervention: Clean filtered air (PM2.5: 5.8 μg/m3)
Number of subjects: 36
Study 32521904 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX (Gemcitabine and Oxaliplatin)
Number of subjects: 68
Study 32521904 — intervention group
Group type: COMPARATOR
Intervention: GDP (Gemcitabine, Cisplatin, and Dexamethasone)
Number of subjects: 68
Study 34001152 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL‐BREF(PT) instrument
Number of subjects: 351
Study 32007179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Disability Scale for Low Back Pain
Number of subjects: 162
Study 36311243 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation + blood flow restriction training (RR + BFRT)
Number of subjects: 40
Study 36311243 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation (RR)
Number of subjects: 40
Study 32965030 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Calendula officinalis
Number of subjects: 82
Study 32965030 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Sorbolene: 10% glycerine in cetomacragol cream)
Number of subjects: 82
Study 35870478 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision support system (CDSS) for antimicrobial stewardship
Number of subjects: 11384
Study 35870478 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic stewardship measures (Control)
Number of subjects: 11384
Study 32864723 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual plus consultations with a patient navigator (oncology nurse)
Number of subjects: 89
Study 32864723 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 89
Study 35511938 — intervention group
Group type: EXPERIMENTAL
Intervention: Vopratelimab with Nivolumab
Number of subjects: 201
Study 33994311 — intervention group
Group type: EXPERIMENTAL
Intervention: IN·clued program
Number of subjects: 1401
Study 33994311 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1401
Study 36097326 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based, peer-led diabetes self-management intervention
Number of subjects: 25
Study 33249467 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg (or dose-reduced 30 mg)
Number of subjects: 614
Study 33249467 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 614
Study 33249467 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 614
Study 33249467 — intervention group
Group type: COMPARATOR
Intervention: VKA
Number of subjects: 614
Study 36193812 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 or 600 mL m‐2 of cow's milk
Number of subjects: 51
Study 36193812 — intervention group
Group type: COMPARATOR
Intervention: Matching equienergetic sugar water (control)
Number of subjects: 51
Study 34371381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 495
Study 34371381 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 495
Study 32878764 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACON Caresystem (model-based decision support system)
Number of subjects: 274
Study 32878764 — intervention group
Group type: COMPARATOR
Intervention: Routine care (current care)
Number of subjects: 274
Study 34798726 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous exhaust‐only ventilation system
Number of subjects: 40
Study 34798726 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent powered central‐fan‐integrated‐supply (CFIS) system
Number of subjects: 40
Study 34798726 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous balanced system with an energy recovery ventilator (ERV)
Number of subjects: 40
Study 33398627 — intervention group
Group type: EXPERIMENTAL
Intervention: mRYGB
Number of subjects: 45
Study 33398627 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 45
Study 33398627 — intervention group
Group type: COMPARATOR
Intervention: GCP
Number of subjects: 45
Study 35147719 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated TKA
Number of subjects: 120
Study 35147719 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 120
Study 35147719 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IL-8 values
Number of subjects: 120
Study 32970234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hayward green kiwifruit with beef meal
Number of subjects: 12
Study 32970234 — intervention group
Group type: COMPARATOR
Intervention: Hort 16A gold kiwifruit with beef meal
Number of subjects: 12
Study 32673233 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided web-based self-management intervention (iFightDepression tool)
Number of subjects: 348
Study 32673233 — intervention group
Group type: COMPARATOR
Intervention: Web-based progressive muscle relaxation (active control)
Number of subjects: 348
Study 32673233 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided web-based self-management intervention
Number of subjects: 348
Study 33689454 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-Loop Control (CLC) system
Number of subjects: 100
Study 36172955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-led intervention with motivational interviewing during weekly calls
Number of subjects: 187
Study 36172955 — intervention group
Group type: COMPARATOR
Intervention: Minimal nonclinical staff support
Number of subjects: 187
Study 33465772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year
Number of subjects: 191
Study 33465772 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of anti-VEGF therapy after 1 year of treatment
Number of subjects: 191
Study 34214881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinkers (>0 g/day of alcohol intake)
Number of subjects: 1783
Study 34214881 — intervention group
Group type: COMPARATOR
Intervention: Non-drinkers (0 g/day of alcohol intake)
Number of subjects: 1783
Study 34608857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel PAP
Number of subjects: 0
Study 34608857 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 0
Study 34252635 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) administration
Number of subjects: 50
Study 36243123 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study 33104258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfotanshinone sodium injection combined with tirofiban (n = 99)
Number of subjects: 169
Study 33104258 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban alone (n = 70)
Number of subjects: 169
Study 34519099 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Diet Replacement (TDR)
Number of subjects: 34
Study 34519099 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Diet Replacement (TDR) with continued behavioural support
Number of subjects: 34
Study 34519099 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural support
Number of subjects: 34
Study 32209067 — intervention group
Group type: EXPERIMENTAL
Intervention: Food and beverage advertisements
Number of subjects: 1610
Study 32209067 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertisements on weekends, afternoons, and during soap operas
Number of subjects: 1610
Study 32209067 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnational and local food and beverage companies
Number of subjects: 1610
Study 32828785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium supplements
Number of subjects: 5147
Study 32828785 — intervention group
Group type: COMPARATOR
Intervention: No calcium supplements
Number of subjects: 5147
Study 32196110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal gelified ethanol injection (Discogel)
Number of subjects: 36
Study 32196110 — intervention group
Group type: COMPARATOR
Intervention: Intradiscal combination of pulsed radiofrequency and gelified ethanol injection (PRF+Discogel)
Number of subjects: 36
Study 32146259 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fractions of 13.5 Gy
Number of subjects: 170
Study 32146259 — intervention group
Group type: COMPARATOR
Intervention: Single fraction of 19 Gy
Number of subjects: 170
Study 36279690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal laser therapy (2 courses within 1 month)
Number of subjects: 43
Study 36279690 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid suppositories (3 times/week for 3 months)
Number of subjects: 43
Study 33561528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 193
Study 33561528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 32723843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM system
Number of subjects: 0
Study 32723843 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study 35871944 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 18
Study 35871944 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 18
Study 32584072 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported social support
Number of subjects: 0
Study 32107188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 277
Study 32107188 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 277
Study 37354171 — intervention group
Group type: EXPERIMENTAL
Intervention: AI algorithm for detecting paroxysmal AF from ECGs in SR
Number of subjects: 142310
Study 35379314 — intervention group
Group type: EXPERIMENTAL
Intervention: Active daily use of Alpha-Stim AID for 8 weeks
Number of subjects: 0
Study 35379314 — intervention group
Group type: COMPARATOR
Intervention: Sham Alpha-Stim AID
Number of subjects: 0
Study 32427325 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Centered Pediatric Advance Care Planning for Teens With Cancer intervention (Session 1 of 3 sessions)
Number of subjects: 80
Study 35922234 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 4280
Study 35922234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 4280
Study 35922234 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk-adapted screening approach
Number of subjects: 4280
Study 33352495 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal drug of Coccinia grandis (500 mg once daily for three months)
Number of subjects: 158
Study 33352495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for three months)
Number of subjects: 158
Study 32812025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg), Daclatasvir (60 mg), Ribavirin (1200 mg)
Number of subjects: 48
Study 32812025 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 33789151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic trials
Number of subjects: 4337
Study 33172290 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole
Number of subjects: 800
Study 33172290 — intervention group
Group type: COMPARATOR
Intervention: Fresco
Number of subjects: 800
Study 33172290 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exposure to Atole
Number of subjects: 800
Study 33172290 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting during early childhood among girls
Number of subjects: 800
Study 33172290 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at first pregnancy (<20 years)
Number of subjects: 800
Study 36169938 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 3 months of DAPT
Number of subjects: 2993
Study 36169938 — intervention group
Group type: COMPARATOR
Intervention: Prolonged DAPT
Number of subjects: 2993
Study 33451691 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Musculoskeletal Function Assessment (SMFA)
Number of subjects: 136
Study 33451691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Extremity Functional Scale (LEFS)
Number of subjects: 136
Study 33451691 — intervention group
Group type: COMPARATOR
Intervention: EuroQoL-5D (EQ-5D)
Number of subjects: 136
Study 32273256 — intervention group
Group type: EXPERIMENTAL
Intervention: SSN Imaging Reporting System (SSN‐IRS)
Number of subjects: 437
Study 34735388 — intervention group
Group type: EXPERIMENTAL
Intervention: Total capture drape
Number of subjects: 68
Study 34735388 — intervention group
Group type: COMPARATOR
Intervention: Standard drape
Number of subjects: 68
Study 36202933 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 90
Study 36202933 — intervention group
Group type: COMPARATOR
Intervention: Oral eplerenone
Number of subjects: 90
Study 36202933 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose PDT (crossover treatment)
Number of subjects: 90
Study 33986477 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (Darbe) 10 μg/kg IV
Number of subjects: 21